

Quick Update:

- CABARET study: 8 months ahead of schedule!
- Membership: 251 members
- COGNO ASM 2012: 7-9 August



COGNO

COOPERATIVE TRIALS GROUP
FOR NEURO-ONCOLOGY

Member Newsletter

Issue 12

Autumn 2012

Message from our Chair



Welcome to another COGNO newsletter. As usual, I'm delighted to report that COGNO continues to thrive with an expanding membership, bewildering accrual to one of our trials and an array of opportunities to participate in educational and scientific discourse. Importantly the expanding membership is increasingly multi-disciplinary with a wide range of vocations now being represented.

As you will read below, the CABARET study has been an outstanding success from an accrual point of view and is a credit to COGNO, our Sites and the PI, Kathryn Field. We hope that a number of significant scientific publications will result from the study. Just as important, the conduct and accrual on CABARET (and CATNON) has established COGNO as a serious player in the world of neuro-oncology clinical research. Similarly, the SEED study is building momentum and promises to provide some initial answers to a major clinical issue: that of steroid use.

Finally, please take note of the upcoming COGNO ASM and the recently-held Clinical Professional day - both events providing tremendous learning and education opportunities for our members.

Mark Rosenthal
Group Chair

Inside this issue:

Chairman's Message	1
COGNO ASM 2012	1
CABARET Update	2
CATNON Update	3
SEED Update	3
Membership Update	4
New Concepts	4
COGNO Team Update	4
COSA Neuro-onc CPD	4
Reminders	4

COGNO 5th ANNUAL SCIENTIFIC MEETING (ASM)

Tuesday–Thursday, 7-9 August 2012
Sofitel Brisbane, 249 Turbot St, Brisbane

The 5th COGNO Annual Scientific Meeting, *Neuroimaging: Novel Approaches for Glioma*, will take place from Tuesday 7th Thursday 9th August 2012, at the Sofitel Brisbane. The ASM will be held in conjunction with the Medical Oncology Group of Australia (MOGA) ASM (8th-11th August), with a highlight being a half-day Joint Neuro-Oncology Symposium with MOGA on 9th August. A preliminary program, featuring International Speakers, Professor Susan Chang and Dr Michael Vogelbaum, is available on the COGNO ASM website <http://www.cogno.org.au/content.aspx?page=cognoasm2012>

Abstract Submissions now open! Please note that submissions close **20 April 2012** - be sure to get your submissions in on time. Two prizes will be offered this year to the two best abstracts. Each prize is valued at \$500 courtesy of Brainlab. Further details are available on <http://www.cogno.org.au/content.aspx?page=cognoasm2012abstract>.

Confirmed international speakers:



Prof Susan Chang
MD

Director

Division of
Neuro-Oncology

University
of California, USA



Dr Michael Vogelbaum
MD PhD

Associate Director

Brain Tumor & Neuro-
Oncology Center

Cleveland Clinic, USA

STUDY & TRIAL UPDATES

CABARET Study: A randomised phase II study of Carboplatin and Bevacizumab in Recur-rent Glioblastoma Multiforme (GBM)



Dr Kathryn Field
CABARET PI

The CABARET Study continues to progress in leaps and bounds with recruitment to part 1 of the study now closed after reaching our recruitment target. Our final patient was randomised on the 15 March 2012, almost 8 months ahead of schedule.

Monash Medical Centre finished on top of the recruitment ladder with Royal Melbourne Hospital a close second and Royal Prince Alfred and St Vincent's (Melbourne) Hospitals not far behind. 122 patients were recruited to Part 1 of the study, with 23 patients continuing on to Part 2 so far. The emphasis now will be on increasing the number of patients continuing on to Part 2 of the study.

The collection of tumour and plasma samples for the CABARET translational substudy continues. We would like to take this opportunity to remind site staff to ensure all patients are given the opportunity to participate in the substudy. The more samples we can collect, the more likely we are to have a meaningful outcome.

As always, a huge thank you to all the site staff involved with making the study run so successfully. Our fantastic recruitment numbers are a reflection of your continued efforts and commitment.

For more information or queries, please contact the team on cabaret@ctc.usyd.edu.au

CABARET Recruitment by Site						
No.	Site name	State	Principal Investigator	Date activated	No. of patients randomised	
					Part 1	Part 2
61331	Monash Medical Centre	VIC	Dr Ronnie Freilich	13 May 2011	17	3
61301	Royal Melbourne Hospital	VIC	Dr Kathryn Field	20 Apr 2011	16	4
61201	Royal Prince Alfred Hospital	NSW	Prof John Simes	5 Nov 2011	13	2
61303	St Vincent's Hospital (Melbourne)	VIC	Dr Anthony Dowling	18 May 2011	11	2
61312	Epworth Healthcare	VIC	Dr Ross Jennens	22 Aug 2011	9	3
61512	The Queen Elizabeth Hospital	SA	Dr William Kevin Patterson	4 Jul 2011	8	2
61319	Austin Hospital	VIC	Dr Lawrence Cher	18 Apr 2011	7	1
61245	Calvary Mater Newcastle	NSW	Dr Fiona Abell	3 Aug 2011	7	0
61202	Royal North Shore Hospital	NSW	Dr Helen Wheeler	17 Mar 2011	6	2
61204	Prince of Wales Hospital	NSW	Dr Liz Hovey	22 Mar 2011	6	1
61401	Royal Brisbane & Womens Hosp.	QLD	Dr Po-Ling Inglis	9 Jun 2011	5	1
61601	Sir Charles Gairdner Hospital	WA	Prof Anna Nowak	27 Oct 2011	5	0
61501	Royal Adelaide Hospital	SA	Dr Nimit Singhal	19 Oct 2011	5	0
61280	Port Macquarie Base Hospital	NSW	Dr Stephen Begbie	28 Jul 2011	4	1
61435	Mater Adult Hospital	QLD	Dr Zarnie Lwin	27 Oct 2011	1	1
61701	Royal Hobart Hospital	TAS	Dr Rosemary Harrup	6 Apr 2011	1	0
61704	Launceston General Hospital	TAS	Dr Stan Gauden	17 Feb 2011	1	0
61305	The Alfred	VIC	Dr Sanjeev Gill	30 Nov 2011	0	0
TOTAL NUMBER of ACTIVE SITES					18	
TOTAL NUMBER of PATIENTS RANDOMISED				Part 1	122 (closed)	
				Part 2	23	

STUDY & TRIAL UPDATES

CATNON (EORTC 26053-22054): Phase III trial on concurrent and adjuvant Temozolomide chemotherapy in non-1p/19q deleted anaplastic glioma.

The holiday period has been quieter than usual for the CATNON Trial (the same trend was observed in the previous year). We hope that this is not an indication of the year ahead! The CATNON trial has now registered 62 patients and randomised 32 patients in total from 10 active sites.

Congratulations to Dr Katharine Cuff and her research team at the Princess Alexandra Hospital for being the first Queensland site to be activated to the CATNON Trial. The site is in the process of registering their first patient and hopefully more patients to follow. To date we have activated 10 sites and work is underway to activating 1 more site in the next few weeks. We will be looking into activating Westmead Hospital to add to the recruiting sites in NSW.

Recent processes have also been circulated to all sites regarding requirements for tumour sample shipments to the EORTC in the Netherlands. So far, the processes have proven effective in ensuring that the correct requirements and timing for shipment are met.

The Site Coordinators continue to do a fantastic job in keeping on top of submitting the case report forms and queries. Additionally, other activities include the processing of the next batch of the Quality Assurance Radiotherapy requests from the EORTC.

As always, the CATNON Coordinating Centre welcomes all suggestions, queries and any assistance we can provide. Please drop us an email at catnon@ctc.usyd.edu.au.

CATNON Recruitment by Site							
No.	Site name	State	Principal Investigator	Date activated	No. of patients registered	No. of patients deemed ineligible	No. of patients randomised
1	Royal North Shore Hospital	NSW	Helen Wheeler	20-Aug-10	23	7	15
2	Royal Hobart Hospital	TAS	Rosie Harrup	8-Sep-10	4	1	3
3	Austin Health	VIC	Lawrence Cher	21-Jun-10	11	8	2
4	Sir Charles Gairdner Hospital	WA	Anna Nowak	29-Sep-10	9	5	4
5	The Alfred	VIC	Sanjeev Gill	31-Aug-11	5	2	3
6	St. Vincents Hospital Melbourne	VIC	Anthony Dowling	22-Mar-11	3	2	2
7	Royal Melbourne Hospital	VIC	Mark Rosenthal	3-Sep-10	3	1	2
8	Flinders Medical Centre	SA	Ganessan Kichenadasse	26-Jul-11	3	2	1
9	Royal Prince Alfred Hospital	NSW	John Simes	11-Mar-11	0	0	0
10	Princess Alexandra Hospital	QLD	Katharine Cuff	14-Dec-11	1	1	0
Total					62	29	32

SEED Study: Self-reported evaluation of the adverse effects of dexamethasone

The SEED study is slowly but steadily progressing in terms of recruitment. Sacred Heart is currently leading the recruitment with 10 patients registered with Braeside closely behind with 8 patients. The study will remain open to recruitment until at least the end of 2012. The target population is 50 patients and their caregivers, of which 25 patients are required to have a primary brain tumour and the remaining 25 patients can comprise of either brain metastases or advanced cancer. Currently only 5/18 patients recruited to the study have a primary brain tumour. Emphasis will be on recruiting more patients with primary brain tumours.

For more information or queries, please contact the team on seed@ctc.usyd.edu.au

SEED Recruitment by Site					
No.	Site name	State	Principal Investigator	Date activated	No. of patients registered
61297	Braeside Hospital	NSW	A/Prof Meera Agar	5 JUL 2011	8
61245	Calvary Mater Newcastle	NSW	Dr Katherine Clark	5 JUL 2011	0
61212	Sacred Heart Hospice	NSW	A/Prof Richard Chye	22 AUG 2011	10
61298	Greenwich Hospital	NSW	Dr Melanie Lovell	1 SEP 2011	0
61213	Liverpool Hospital	NSW	A/Prof Meera Agar	23 SEP 2011	0
TOTAL NUMBER of ACTIVE SITES					5
TOTAL NUMBER of PATIENTS REGISTERED					18



COGNO CONTACTS

Ann Livingstone

Associate Oncology Program
Manager (Mon, Tues & Wed)
E: ann.livingstone@ctc.usyd.edu.au
T: (02) 9562 5332

Alan Lucas

CATNON Trial Coordinator
E: alucas@ctc.usyd.edu.au
or catnon@ctc.usyd.edu.au
T: (02) 9562 5314

Kate Sawkins

CABARET Trial Coordinator
E: cabaret@ctc.usyd.edu.au
T: (02) 9562 5374

Bhagwant Sekhon

SEED Trial Coordinator
(Wed, Thurs & Fri)
E: seed@ctc.usyd.edu.au
T: (02) 9562 5391

Bernadette Tomes

Clinical Trials Assistant
E:
bernadette.tomes@ctc.usyd.edu.au
T: (02) 9562 5321

Rasha Cosman

Clinical Research Fellow
E: rasha.cosman@ctc.usyd.edu.au
T: (02) 9562 7111

Jenny Chow

Executive Officer (Tues, Wed)
E: cognoeo@ctc.usyd.edu.au
T: (02) 9562 5389

COGNO Coordinating Centre
NHMRC Clinical Trials Centre
Locked Bag 77
Camperdown NSW 1450
T: +61 2 9562 5000
F +61 2 9562 5094
E: cogno@ctc.usyd.edu.au

MEMBERSHIP UPDATE

We now have 251 members! Our numbers are steadily increasing, though we are yet to welcome our first member from the Northern Territory. Help us expand our Group's expertise and networking capacity. If you know someone who would like to join, you can now refer prospective members to our online membership application on our website (www.cogno.org.au) or to the COGNO Coordinating Centre on cogno@ctc.usyd.edu.au.

NEW CONCEPTS

DO YOU HAVE A NEW CONCEPT? COGNO is always looking to develop new studies—from inception through to full protocol development and managing feasibility and operational issues. We aim to help progress and support development of important clinical trial questions. So if you would like to propose a concept for a COGNO clinical trial, please contact us on cogno@ctc.usyd.edu.au or complete and return our Trial Concept Outline form available at www.cogno.org.au.

(The next COGNO Scientific Advisory Committee is scheduled for 18th April 2012 - if you would like the SAC to consider your concept for a project proposal, please complete and submit the Trial Concept Outline form mentioned above by 2nd April 2012).

COGNO TEAM UPDATE



We are pleased to introduce Dr Rasha Cosman, COGNO's Clinical Research Fellow, who commenced in February. Rasha graduated from UNSW and is currently a third year medical oncology trainee having trained at St George and Prince of Wales Hospitals. She attended ACORD in 2010 and has looked after trial patients in the clinical setting throughout her training. Rasha looks forward to widening her research experience this year by being involved in clinical trials at their various stages from concept development to reporting. Welcome Rasha!

Left to right: Jenny Chow, Kate Sawkins, Ann Livingstone, Alan Lucas, Rasha Cosman

COSA NEURO-ONCOLOGY CLINICAL PROFESSIONAL DAY



Our congratulations to the COSA Neuro-Oncology Group, chaired by COGNO member Dr Eng-Siew Koh, on organising a very successful Neuro-Oncology Clinical Professional Day on 9 March. The program, Brain Tumours: New tools for diagnosis, treatment and research, which included international guest speakers Professor Martin van den Bent and Professor Paul Kleihues, as well as a number of Australian experts, was very educational and relevant. Dr Koh reported 161 attendees across all health disciplines and including consumer advocates (as well as many COGNO members), and a waiting list of 13.

Left to right:

Front row: Dr Elizabeth Hovey, Dr Eng-Siew Koh

Middle row: Dr Michael Rodriguez, Dr Michael Buckland, Prof Martin van den Bent, Dr Lindy Jeffree
Back row: A/Prof Michael Back, Prof Paul Kleihues, Dr Rob Ware, Dr Kerrie McDonald

REMINDERS

- **Brain Tumour Support & Education Forum** will be held at The Menzies Hotel Sydney, 10 May 2012 <http://www.cancerinstitute.org.au/events/i/brain-tumour-support-and-education-forum-2012>
- **COGNO's 5th Annual Scientific Meeting**, Sofitel Brisbane, Queensland, 7th-9th August 2012, in conjunction with the MOGA Annual Scientific Meeting (8th-11th August). Refer the COGNO ASM website <http://www.cogno.org.au/content.aspx?page=cognoasm2012> and the MOGA ASM website <http://www.mogaasm2012.com/>, and keep an eye out for updates via COGNO member emails.